Cargando…

Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis

BACKGROUND: Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization–recommended or higher doses of first-line drugs achieve successful outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solans, Belén P, Béranger, Agathe, Radtke, Kendra, Mohamed, Ali, Mirzayev, Fuad, Gegia, Medea, Linh, Nguyen Nhat, Schumacher, Samuel G, Nahid, Payam, Savic, Radojka M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156125/ https://www.ncbi.nlm.nih.gov/pubmed/36609692 http://dx.doi.org/10.1093/cid/ciac973

Ejemplares similares

World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
por: Mirzayev, Fuad, et al.
Publicado: (2021)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Kloprogge, Frank, et al.
Publicado: (2020)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Pharmacokinetic analysis across studies to drive knowledge‐integration: A tutorial on individual patient data meta‐analysis (IPDMA)
por: van Wijk, Rob C., et al.
Publicado: (2023)

Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial
por: Solans, Belén P, et al.
Publicado: (2023)

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials
por: Imperial, Marjorie Z., et al.
Publicado: (2021)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
por: Savic, Radojka M., et al.
Publicado: (2022)

Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
por: Huo, Fengmin, et al.
Publicado: (2020)

Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing
por: Garcia‐Cremades, Maria, et al.
Publicado: (2020)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

New insights on tuberculosis transmission dynamics and drug susceptibility profiles among the prison population in Southern Brazil based on whole-genome sequencing
por: Anselmo, Lívia Maria Pala, et al.
Publicado: (2023)

Assessment of factors associated with potential drug-drug interactions in patients with tuberculosis and HIV/AIDS
por: de Resende, Natália Helena, et al.
Publicado: (2021)

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis
por: Gupta, Aastha, et al.
Publicado: (2022)

Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis
por: Fors, John, et al.
Publicado: (2020)

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
por: Nahid, Payam, et al.
Publicado: (2011)

Prevalence of Intestinal Helminth Coinfection in Drug-Resistant Tuberculosis in Uganda
por: Baluku, Joseph Baruch, et al.
Publicado: (2022)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
por: Shrestha, Sourya, et al.
Publicado: (2014)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam
por: Nagot, Nicolas, et al.
Publicado: (2021)

Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis
por: Padmapriydarsini, Chandrasekaran, et al.
Publicado: (2021)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

Comparative Effectiveness of Regimens for Drug-Susceptible Tuberculous Meningitis in Children and Adolescents: A Systematic Review and Aggregate-Level Data Meta-Analysis
por: Sulis, Giorgia, et al.
Publicado: (2022)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Importance of Drug Pharmacokinetics at the Site of Action
por: Rizk, ML, et al.
Publicado: (2017)

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
por: Schulte, Benjamin, et al.
Publicado: (2020)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )
por: Huerga, Helena, et al.
Publicado: (2022)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Understanding Nonadherence to Tuberculosis Medications in India Using Urine Drug Metabolite Testing: A Cohort Study
por: Subbaraman, Ramnath, et al.
Publicado: (2021)

Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring
por: Ashkin, Alex, et al.
Publicado: (2023)

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies
por: Alipanah, Narges, et al.
Publicado: (2018)

Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer
por: Jayachandran, Priya, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0510oqksodjsa75jptdr0ta90k